Street Calls of the Week
ARS Pharmaceuticals Inc. stock reached a 52-week low, touching a price of 9.97 USD, with the stock now 47% below its 52-week high of 18.90 USD. This marks a significant decline for the company, with a 1-year return of -9.02%. According to InvestingPro analysis, the stock’s RSI indicates oversold conditions, suggesting potential for a technical rebound. The drop reflects ongoing challenges within the pharmaceutical sector and specific hurdles faced by ARS Pharmaceuticals, though the company maintains a healthy balance sheet with a current ratio of 6.17. Investors and analysts will be closely monitoring the company’s performance, with analyst targets ranging from $25 to $40 per share. InvestingPro offers 8 additional key insights and a comprehensive Pro Research Report for deeper analysis of SPRY’s potential.
In other recent news, ARS Pharmaceuticals reported its second-quarter 2025 earnings, revealing a revenue of $15.7 million, which surpassed the forecast of $13.77 million by 14.16%. Despite this revenue beat, the earnings per share (EPS) met the forecast at -$0.46. Furthermore, the company achieved net sales of $12.8 million for its neffy product, with approximately 35,000 neffy 2-packs sold during the quarter. Raymond James has reiterated a Strong Buy rating on ARS Pharmaceuticals, highlighting strong sales of neffy and maintaining a price target of $32.00.
Additionally, Roth/MKM initiated coverage of ARS Pharmaceuticals with a Buy rating, citing the potential of its needle-free epinephrine product, neffy, and setting a price target of $40.00. The product had received regulatory approval six months ago. In another development, ARS Pharmaceuticals received a Paragraph IV certification notice from Lupin Inc., which has submitted an application to the FDA to manufacture a generic version of neffy before the expiration of ARS Pharmaceuticals’ patents. Lupin’s notice challenges the validity and enforceability of several ARS Pharmaceuticals patents.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.